Smart Nanotechnology-Based Drug Delivery Systems: Recent Advances and Future Prospects in Stimuli-Responsive Targeted Therapy

Abstract

Drug Delivery System based on smart nanotechnology allow stimuli-responsive and spatiotemporally regulated therapeutic release, which is a revolutionary development in precision medicine. When compared to traditional drug formulations, engineered nanocarriers, such as liposomes, polymeric nanoparticles, dendrimers, micelles, solid lipid nanoparticle NPs, and hybrid inorganic platforms, display improved bioavailability, reduced off-target toxicity, and superior pharmacokinetic performance. Therapeutic payloads can be released site-specifically and on demand thanks to these nano systems ability to react to endogenous cues (pH, redox gradients, enzymatic activity, and hypoxia) or exogenous stimuli (temperature, light, ultrasonic, magnetic, and electric fields). Their selectivity and biological performance are further enhanced by the incorporation of targeted ligands, surface modifications, and biocompatible materials across intricate pathophysiological barriers, such as the blood–brain barrier and the tumour microenvironment. In cancer, neurodegenerative, cardiovascular, and infectious illnesses, smart nanocarriers have shown encouraging efficacy. They have also opened the door for sophisticated theragnostic applications that combine therapy and diagnostics. Translational issues such as large-scale repeatability, long-term stability, immunogenicity, and regulatory uniformity still exist despite tremendous advancements. These obstacles should be addressed by the confluence of artificial intelligence, 3D/4D printing, and nanorobotics, which will hasten the clinical translation of next-generation intelligent nanomedicines toward tailored and flexible therapy paradigms.